MacroGenics Inc
NASDAQ:MGNX

Watchlist Manager
MacroGenics Inc Logo
MacroGenics Inc
NASDAQ:MGNX
Watchlist
Price: 1.39 USD 4.51% Market Closed
Market Cap: 87.9m USD

MacroGenics Inc
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

MacroGenics Inc
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
MacroGenics Inc
NASDAQ:MGNX
EPS (Diluted)
-$1
CAGR 3-Years
27%
CAGR 5-Years
16%
CAGR 10-Years
-14%
Abbvie Inc
NYSE:ABBV
EPS (Diluted)
$1
CAGR 3-Years
-44%
CAGR 5-Years
-20%
CAGR 10-Years
-2%
Gilead Sciences Inc
NASDAQ:GILD
EPS (Diluted)
$6
CAGR 3-Years
35%
CAGR 5-Years
45%
CAGR 10-Years
-5%
Amgen Inc
NASDAQ:AMGN
EPS (Diluted)
$12
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
EPS (Diluted)
$14
CAGR 3-Years
4%
CAGR 5-Years
7%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
EPS (Diluted)
$42
CAGR 3-Years
-4%
CAGR 5-Years
9%
CAGR 10-Years
24%
No Stocks Found

MacroGenics Inc
Glance View

Market Cap
87.9m USD
Industry
Biotechnology

MacroGenics, Inc. is a clinical-stage biopharmaceutical company, engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. The company is headquartered in Rockville, Maryland and currently employs 427 full-time employees. The company went IPO on 2013-10-10. The company is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is MGC018, an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. The company is also developing enoblituzumab, an Fc-optimized monoclonal antibody (mAb) that targets B7-H3 and molecules that target programmed cell death protein 1 (PD-1), a protein that is important in the regulation of the immune system's response to cancer. Its clinical pipeline includes two bispecific DART product candidates that co-engage both PD-1 and lymphocyte-activation gene 3 (LAG-3) (tebotelimab), and PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) (lorigerlimab). In addition, it is also developing MGD024.

MGNX Intrinsic Value
HIDDEN
Show

See Also

What is MacroGenics Inc's EPS (Diluted)?
EPS (Diluted)
-1.2 USD

Based on the financial report for Sep 30, 2025, MacroGenics Inc's EPS (Diluted) amounts to -1.2 USD.

What is MacroGenics Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
-14%

Over the last year, the EPS (Diluted) growth was 22%. The average annual EPS (Diluted) growth rates for MacroGenics Inc have been 27% over the past three years , 16% over the past five years , and -14% over the past ten years .

Back to Top